Optimizing Workflow Task Allocation in Cloud Computing Environments

Services like newline Infrastructure, Platform, and Software are made possible by cloud computing, an essential technology. It is difficult to distribute available resources and balance the load effectively while providing these services to newline's many cloud customers. There is no need to allocate additional resources to handle requests when using the defragmentation newline approach, which is one way for load balancing. This leads to greater resource utilisation. Lastly, an experimental investigation is conducted using the Cloud Sim tool to demonstrate the approach's applicability. The findings show that suggested mechanisms, such as task consolidation and defragmentation, outperform previous solutions

Acute mountain sickness amongst tourists to Lhasa

Abstract Acute mountain sickness is the commonest acute high altitude illness occurring at high altitude. Its prevalence is dependent on the ascent rate, altitude achieved, physical effort required to reach the target altitude and pharmacological intervention undertaken by the tourists visiting high altitude areas. This Letter to the Editor is an endeavour to re-emphasise the importance of all these factors affecting the prevalence of acute mountain sickness

QSPR Studies on Aqueous Solubilities of Drug-Like Compounds

A rapidly growing area of modern pharmaceutical research is the prediction of aqueous solubility of drug-sized compounds from their molecular structures. There exist many different reasons for considering this physico-chemical property as a key parameter: the design of novel entities with adequate aqueous solubility brings many advantages to preclinical and clinical research and development, allowing improvement of the Absorption, Distribution, Metabolization, and Elimination/Toxicity profile and “screenability” of drug candidates in High Throughput Screening techniques. This work compiles recent QSPR linear models established by our research group devoted to the quantification of aqueous solubilities and their comparison to previous research on the topic

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Although Aurora A, B, and C kinases share high sequence similarity, especially within the kinase domain, they function distinctly in cell-cycle progression. Aurora A depletion primarily leads to mitotic spindle formation defects and consequently prometaphase arrest, whereas Aurora B/C inactivation primarily induces polyploidy from cytokinesis failure. Aurora B/C inactivation phenotypes are also epistatic to those of Aurora A, such that the concomitant inactivation of Aurora A and B, or all Aurora isoforms by nonisoform–selective Aurora inhibitors, demonstrates the Aurora B/C-dominant cytokinesis failure and polyploidy phenotypes. Several Aurora inhibitors are in clinical trials for T/B-cell lymphoma, multiple myeloma, leukemia, lung, and breast cancers. Here, we describe an Aurora A–selective inhibitor, LY3295668, which potently inhibits Aurora autophosphorylation and its kinase activity in vitro and in vivo, persistently arrests cancer cells in mitosis, and induces more profound apoptosis than Aurora B or Aurora A/B dual inhibitors without Aurora B inhibition–associated cytokinesis failure and aneuploidy. LY3295668 inhibits the growth of a broad panel of cancer cell lines, including small-cell lung and breast cancer cells. It demonstrates significant efficacy in small-cell lung cancer xenograft and patient-derived tumor preclinical models as a single agent and in combination with standard-of-care agents. LY3295668, as a highly Aurora A–selective inhibitor, may represent a preferred approach to the current pan-Aurora inhibitors as a cancer therapeutic agent